Comparison of the effects of sugammadex recommended dose (2mg/kg) and fixed dose of 200mg on the reversal of moderate neuromuscular block and recovery profile in adult patients

开始日期2023-09-04

申办/合作机构

Konyang University Hospital

100 项与 Konyang University Hospital 相关的临床结果

登录后查看更多信息

0 项与 Konyang University Hospital 相关的专利（医药）

登录后查看更多信息

1,054

项与 Konyang University Hospital 相关的文献（医药）

2025-12-31·Virulence

Restriction of mitochondrial oxidation of glutamine or fatty acids enhances intracellular growth of Mycobacterium abscessus in macrophages

Article

作者: Park, Hwan-Woo ; Kim, Ho Won ; Lee, Young Ik ; Kim, Jong-Seok ; Yoon, Hoe Sun ; Lee, Ji Won ; Lee, Sung Ki ; Whang, Jake

Mycobacterium abscessus (Mab), a nontuberculous mycobacterium, is increasing in prevalence worldwide and causes treatment-refractory pulmonary diseases. However, how Mab rewires macrophage energy metabolism to facilitate its survival is poorly understood. We compared the metabolic profiles of murine bone marrow-derived macrophages (BMDMs) infected with smooth (S)- and rough (R)-type Mab using extracellular flux technology. Mab infection shifted BMDMs towards a more energetic phenotype, marked by increased oxidative phosphorylation (OXPHOS) and glycolysis, with a significantly greater enhancement in OXPHOS. This metabolic adaptation was characterized by enhanced ATP production rates, particularly in cells infected with S-type Mab, highlighting OXPHOS as a key energy source. Notably, Mab infection also modulated mitochondrial substrate preferences, increasing fatty acid oxidation capabilities while revealing significant changes in glutamine dependency and flexibility. R-type Mab infections exhibited a marked decrease in glutamine reliance but enhanced metabolic flexibility and capacity. Furthermore, targeting metabolic pathways related to glutamine and fatty acid oxidation exacerbated Mab growth within macrophages, suggesting these pathways play a protective role against infection. These insights advance our understanding of Mab's impact on host cell metabolism and propose a novel avenue for therapeutic intervention. By manipulating host mitochondrial metabolism, we identify a potential host-directed therapeutic strategy against Mab, offering a promising alternative to conventional treatments beleaguered by drug resistance. This study underscores the importance of exploring metabolic interventions to combat Mab infection, paving the way for innovative approaches in the fight against this formidable pathogen.

2025-08-01·The Knee

Bidirectional barbed polydioxanone filament insertion in vastus medialis oblique muscle for knee osteoarthritis improvement

Article

作者: Choi, Sung-Woo ; Kim, Chang-Hyun ; Nam, Mi-Ae ; Lee, Dong-Woo ; Lee, Kang-San ; Kim, Hyoung-Ye ; Lee, Byung-Ryul ; Kwon, Sai-Won ; Oh, Byung-Hak

BACKGROUNDStrengthening the quadriceps muscle in patients with knee osteoarthritis (OA) can effectively alleviate symptoms such as pain and swelling. However, the use of bidirectional barbed polydioxanone filament (BBPF) for this purpose remains underexplored. Therefore, this study aimed to evaluate the impact of a new muscle enhancement and support therapy (MEST) involving the insertion of a BBPF into the vastus medialis obliquus (VMO) to improve the symptoms of knee OA.METHODSIn a multicenter, randomized, double-blind study, we evaluated 131 patients over 40 with Kellgren-Lawrence grade II-III medial compartment knee OA. Of these, 88 received BBPF insertion into the VMO (MEST group), and 43 were in the control group. We compared pain levels (via a visual analog scale (VAS) during weight-bearing and walking), quadriceps muscle strength (IMCSQ), Patient Global Impression of Change (PGIC), and Clinical Global Impression of Change (CGIC), assessing outcomes before and after the procedure.RESULTSAt four and eight weeks post-procedure, the VAS scores during weight-bearing and walking were significantly lower in the MEST group compared to the control group (P = 0.001). The differences in the IMCSQ at four and eight weeks post-procedure were significantly higher in the MEST group (P = 0.001). The PGIC and CGIC scores improved significantly at four weeks post-procedure (P = 0.001).CONCLUSIONBy reducing pain, improving function, and increasing muscle strength, MEST shows promise as a valuable addition to current treatment options. The biodegradable nature of the sutures suggests that repeat procedures may be beneficial, warranting further investigation to optimize this technique for wider clinical use.

2025-06-01·Psychiatry Research

Efficacy of digital therapeutic applications for cognitive training among older adults with mild cognitive impairment or dementia: A systematic review and network meta-analysis of randomized controlled trials

Review

作者: Rhee, Taeho Greg ; Lee, Yeo Wool ; Jeong, Hye Su ; Shim, Sung Ryul

Various digital therapeutics (DTx), which utilize computerized cognitive training (CCT) to improve cognitive functioning, have been tested and released. However, the efficacy of these DTx approaches may be diverse. This study aims to meta-synthesize the associations between mobile applications and cognitive functioning outcomes in older adults with mild cognitive impairment (MCI) or dementia from randomized controlled trials (RCTs). We searched PubMed, EMBASE, Scopus, and Cochrane Library from the inception through the end of June 2024. We selected RCTs using mobile application interventions in older adults with MCI or dementia. Interventions and comparisons included: CCT, intensive CCT (CCT2x), computerized cognitive engagement, progressive resistance training (PRT), CCT plus medication, CCT plus PRT, and medications only. Outcomes of interest included cognitive functioning and other measures of functioning (e.g., activities of daily living [ADLs]). Network meta-analysis was conducted to estimate pooled standardized mean differences (SMDs) with corresponding 95 % confidence intervals (CIs). Of 1,189 studies extracted, 10 RCTs were included in our analysis. CCT2x demonstrated statistically significant improvements in global cognitive function (SMD, 1.21 [95 % CI, 0.69-1.73]), episodic memory (SMD, 0.87 [0.47-1.27]), and working memory (SMD, 0.93 [0.44-1.42]) when compared with controls. For ADLs, CCT significantly reduced functional impairment (SMD, -0.80 [-1.40 to -0.21]). In depressive symptoms, CCT2x was the most effective in reducing symptoms (SMD, -0.77 [-1.08 to -0.45]). Overall, the DTx may be effective in improving cognitive and other functioning outcomes in older adults with MCI or dementia.

项与 Konyang University Hospital 相关的新闻（医药）

2024-04-02

·PRNewswire

GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug 'Immuncell-LC' at the AACR Annual Meeting 2024 that will take place in San Diego, California, on April 5-10. Continue Reading GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 "We are looking forward to sharing data that GL205 (GCC2005) effectively targets CD5 in malignant T-cell lymphomas, suggesting it as a new treatment option for patients with limited choices from current approved therapies. Presenting at AACR offers a significant opportunity to globally disseminate our research findings, creating anticipation for the forthcoming clinical trials of GL205 (GCC2005) slated for IND submission this year." said Sungyong Won, CSO of GC Cell. Details for the AACR 2024 abstracts are as follows: Poster Presentation Details Title: Superior anti-tumor activity of GL205, an allogeneic anti-CD5 CAR-NK for treating T-cell malignancies Authors: Miyoung Jung, Seung Min Kim, Eunsol Lee, Hyunseung Sun, Jaeyoung Yoo, Subin An, Jiyoung Park, MiAe Han, Yusun Kim, Sunglim Cho, Bokyung Min Session Title: CAR-NK, NK Engagers, and NK Modulators Session Date and Time: Monday, April 8, 2024 9:00 am PT – 12:40 pm PT Location: Poster Section 2 Poster Board Number: 7 Published Abstract Number: 1324 Title: A retrospective analysis of the clinical characteristics of metastastic solid cancer patients with cytokine-induced killer cells combined immune checkpoint inhibitor immunotherapy Lead Author: Jong Gwon Choi, Division of Oncology and Hematology, Konyang University Hospital, Daejeon, Korea Session Title: Adoptive Cellular Therapy 1 Session Date and Time: Monday, April 8, 2024 1:30 pm PT – 5:00 pm PT Location: Poster Section 39 Poster Board Number: 1 Published Abstract Number: 3595 About Immuncell-LC Immuncell-LC is the only commercially available adoptive cell therapy treatment of early-stage HCC. It is primarily composed of autologous, cultured blood-derived T lymphocytes with proven efficacy through a large-scale Phase 3 clinical trial which reduced the risk of recurrence by 37% and decreased the mortality rate by 79% compared to the control group. To date, Immuncell-LC has been administered to over 10,000 patients in South Korea without serious adverse events. About GC Cell With a core focus on cell therapy, GC Cell offers complete bio healthcare solutions from diagnosis to treatment, and the brand's comprehensive value chain spans R&D, production, commercialization, and distribution. More info: SOURCE GC Cell